January 15, 2020
Kyowa Kirin and partner Ultragenyx said on January 14 that they have submitted a supplemental biologics license application (sBLA) in the US, seeking an additional indication for Crysvita (burosumab) for the treatment of tumor-induced osteomalacia (TIO). The filing was made...read more